Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 57 recruiting now full pipeline #57 of 28,707 conditions

Smoking Cessation: full-pipeline trial registry

57 of 189 indexed Smoking Cessation trials are currently recruiting.

Corpus placement: #57 of 28,707 conditions by registered trial count.

189 US clinical trials · 57 currently recruiting · #57 of 28,707 conditions by registered trial count

Smoking Cessation: 189 US clinical trials tracked, 57 recruiting.

Smoking Cessation is the subject of 189 registered US clinical trials on ClinicalTrials.gov, 57 of them currently open to new participants. 33 are in Phase 3-4 (later-stage) and 30 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, San Francisco, running 10 of these trials.

Enrollment posture brief

Registry condition smoking-cessation

OPEN 57 | RECR 30% | LATE 33 | EARLY 30 | RANK #57 | SPON 10

Nearest open-share peer: Heart Diseases (30% recruiting · 86 trials)

Advanced Solid Tumor70%Endometrial Cancer57.4%Myelodysplastic Syndromes37.8%Chronic Lymphocytic Leukemia34.4%Smoking Cessation (this)30%
Open-enrollment share among volume-matched conditions near Smoking Cessation

Smoking Cessation lists 57 open slots (30% of 189 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Smoking Cessation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Smoking Cessation is recruiting below its size-band peers.

    57 of 189 indexed trials (30.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Smoking Cessation trials is spread across many organizations.

    University of California, San Francisco accounts for 10 of 189 trials (5.3%). 84 distinct sponsors appear on at least one study for this condition label.

  3. Typical Smoking Cessation enrolment sits around 200 participants.

    Median target enrolment is 200 among the 189 trials that report a genuine target (sentinel values excluded). 71 of those (37.6%) plan for fewer than 100 participants.

  4. Smoking Cessation research is mostly interventional.

    181 interventional and 8 observational studies make up this index (95.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 115Phase 215Phase 314Phase 419

Open and recent trials

189 total, page 4 of 4

COMPLETED NA 76 participants

Increasing Cessation Motivation and Treatment Engagement Among Smokers in Pain

Syracuse University

NCT03996902

COMPLETED Phase 1 73 participants

A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers

Pfizer

NCT00463918

COMPLETED NA 70 participants

Integrating the Quit and Stay Quit Monday Model Into Smoking Cessation Services for Smokers With Mental Health Conditions

NYU Langone Health

NCT04512248

COMPLETED Phase 1 70 participants

Intervention for Support Persons to Help Smokers Quit

Mayo Clinic

NCT00379054

COMPLETED NA 69 participants

Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)

Duke University

NCT01055886

COMPLETED 62 participants

Helping Moms Who Smoke

University of Kansas Medical Center

NCT03104452

COMPLETED NA 61 participants

Connecting Alaska Native People to Quit Smoking

Mayo Clinic

NCT03645941

COMPLETED NA 60 participants

Development and Pilot Testing of the Sense2Quit App

Columbia University

NCT05609032

COMPLETED Phase 2 58 participants

AXS-05 Phase II Trial on Smoking Behavior

James Davis

NCT03471767

COMPLETED Early Phase 1 56 participants

End Nicotine Dependence Clinic

Case Comprehensive Cancer Center

NCT03290430

COMPLETED NA 55 participants

A Multiple Health Behavior Change Intervention for Overweight and Obese Smokers

Brown University

NCT05136430

COMPLETED Phase 4 52 participants

Tobacco Treatment Comparison for Cancer Care

University of Wisconsin, Madison

NCT06218823

COMPLETED NA 52 participants

Impact of E-cigarette Nicotine Concentration on Compensation

University of Kansas Medical Center

NCT05887947

COMPLETED Early Phase 1 50 participants

Applying mHealth to Tobacco-related Health Disparities

H. Lee Moffitt Cancer Center and Research Institute

NCT03404596

COMPLETED NA 44 participants

Hospital-based Patient Navigation and Smoking Cessation

Boston Medical Center

NCT03452371

COMPLETED 43 participants

Smoking, Stress & Allopregnanolone Response

University of Minnesota

NCT02087800

COMPLETED NA 42 participants

VIDeOS for Smoking Cessation

Medical University of South Carolina

NCT06307496

COMPLETED NA 40 participants

Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery

Yale University

NCT02402023

COMPLETED Phase 2 40 participants

Varenicline for Treatment of E-cigarette Dependence

Yale University

NCT05541497

COMPLETED Phase 2 38 participants

Treating Smokers With Mental Illness

University of Minnesota

NCT03822416

COMPLETED Phase 2 36 participants

Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate

Jed E. Rose

NCT01857531

COMPLETED Phase 1 33 participants

Contingency Management, Quitting Smoking, and ADHD

Duke University

NCT02266784

COMPLETED Phase 1 30 participants

Preventing Postpartum Relapse to Smoking Using Yoga and Cognitive Behavioral Therapy: A Randomized Pilot Study

University of Pittsburgh

NCT00360581

COMPLETED NA 29 participants

Enhancing Relapse Prevention for Smoking Cessation With Repetitive Transcranial Magnetic Stimulation

The City College of New York

NCT02822703

COMPLETED Phase 1 26 participants

Harnessing the Power of Technology: MOMBA for Postpartum Smoking

Yale University

NCT02237898

COMPLETED Phase 2 24 participants

Varenicline and Smoking Cessation in Schizophrenia

University of Minnesota

NCT01111149

COMPLETED NA 22 participants

Randomized Pilot Study of a mHealth App for Ambivalent Smokers Living With HIV

Kaiser Permanente

NCT05339659

COMPLETED Phase 4 20 participants

Smartphone-delivered Automated Video-assisted Smoking Treatment for Patrons of a Food Resource Center

University of Oklahoma

NCT03060278

COMPLETED NA 20 participants

Empowering LGBTQ+ Tobacco Cessation Pilot

University of Oklahoma

NCT05365633

COMPLETED NA 20 participants

Mobile Contingency Management for Smoking Cessation (R01 Supplement) (PrevailGO)

University of Oklahoma

NCT03517397

COMPLETED NA 20 participants

Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation

Stanford University

NCT05220254

COMPLETED NA 18 participants

Tobacco Cessation in Public Housing

Johns Hopkins University

NCT04889638

COMPLETED NA 18 participants

SmokefreeSGM, A Text-based Smoking Cessation Intervention for Sexual and Gender Minority Groups

The University of Texas Health Science Center, Houston

NCT05029362

COMPLETED NA 18 participants

Mindfulness Based Smoking Cessation Program

Boston Medical Center

NCT02795312

COMPLETED Phase 2 14 participants

Suvorexant to Reduce Symptoms of Nicotine Use

The University of Texas Health Science Center, Houston

NCT04234997

COMPLETED Early Phase 1 13 participants

Smoking by IV Pulsed Nicotine

Yale University

NCT04488744

COMPLETED NA 10 participants

HCV-Smoking Cessation Study

Prisma Health-Upstate

NCT05466981

COMPLETED NA 9 participants

Designing an Implementation Strategy for Lung Screening and Smoking Cessation Treatment in Community Health Centers

University of Colorado, Denver

NCT05447897

COMPLETED Early Phase 1 7 participants

Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder

Medical University of South Carolina

NCT05796791

← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 15
Phase 3 14
Phase 4 19

Named interventions

Most-linked intervention names on Smoking Cessation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Varenicline Drug
15 trials
Nicotine patch Drug
9 trials
Placebo Drug
7 trials
Bupropion Drug
6 trials
Nicotine Patch Drug
6 trials
Counseling Behavioral
5 trials
Nicotine lozenge Drug
4 trials
Smoking Cessation Counseling Behavioral
3 trials

US sites by state

Facility locations filed on Smoking Cessation trials. A trial with sites in several states counts in each.

California 25 trials
New York 22 trials
Massachusetts 18 trials
Florida 15 trials
Texas 14 trials
South Carolina 14 trials
Minnesota 14 trials
North Carolina 13 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Smoking Cessation page

189 registered trials, 57 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Smoking Cessation condition card totals 189 registered trials; most-linked intervention Varenicline; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.